Pulmonary vascular disease & thromboembolism
Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis
Authors' conclusion
The incidence of adverse events in home-treated PE patients, selected by a validated triage tool, was very low.
Study context
- Population
- Acute pulmonary embolism (PE) patients treated at home (discharged within 24 h), selected by a predefined triage tool
- Participants
- 2,694 patients10 studies
- Outcome
- All-cause mortality and adverse events (recurrent VTE, major bleeding and/or all-cause mortality)
- Follow-up
- 14 and 30 days
Methodological detailssystematic search, random effects model
- Systematic search
- Random effects model
Pooled result
As reported in the abstract
14-day mortality
0.11%
95% CI 0.0–0.24, I2 = 0
30-day mortality
0.30%
95% CI 0.09–0.51, I2 = 0
14-day adverse events
0.56%
95% CI 0.28–0.84, I2 = 0
30-day adverse events
1.2%
95% CI 0.79–1.6, I2 = 0
Further pooled results
30-day mortality, by cancer (subgroup)
| RR (95% CI) | ||
|---|---|---|
| CancerPrediction interval; I2 = 0 | 4.9 (2.7–9.1) | |
| 0.10.31310Relative risk (log scale) |
14-day adverse events, by subgroup
| RR (95% CI) | ||
|---|---|---|
| Pre-existing cardiopulmonary diseasePrediction interval; I2 = 0 | 3.5 (1.5–7.9) | |
| Abnormal troponinPrediction interval; I2 = 0 | 2.5 (1.3–4.9) | |
| Abnormal (NT-pro)BNPPrediction interval; I2 = 0 | 3.9 (1.6–9.8) | |
| 0.10.31310Relative risk (log scale) |
30-day adverse events, by subgroup
| RR (95% CI) | ||
|---|---|---|
| CancerPrediction interval; I2 = 0 | 2.7 (1.4–5.2) | |
| Abnormal troponinPrediction interval; I2 = 0 | 2.9 (1.5–5.7) | |
| Abnormal (NT-pro)BNPPrediction interval; I2 = 0 | 3.3 (1.6–7.1) | |
| 0.10.31310Relative risk (log scale) |
14-day adverse events, by subgroup
- Not associated with increased mortality
Original publication
Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis. Eur Heart J. Published 12 July 2024. doi:10. 1093/ eurheartj/ ehae378
Composed by AI from the published abstract and checked against it. How Briefs are made →